IP Library Granted Patent US 7,696,189
Granted Patent B1
US 7,696,189 · App. 11/835,394 · Granted Apr 13, 2010

Prostate and breast cancer treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,696,189
App. No.
11/835,394
Granted
Apr 13, 2010
Kind
B1
Abstract

The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.

Claims (23)

1. A pharmaceutical formulation comprising one or more excipients and group 2 compound selected from the group consisting of

2. The pharmaceutical formulation of claim 1 wherein the compound is

3. The pharmaceutical formulation of claim 1 wherein the compound is

4. The pharmaceutical formulation of claim 1 wherein the compound is

5. The pharmaceutical formulation of claim 1 wherein the pharmaceutical formulation is a dosage form for oral or parenteral administration.

6. A pharmaceutical formulation comprising one or more excipients and a group 3 compound selected from the group consisting of

7. The pharmaceutical formulation of claim 6 wherein the compound is

8. The pharmaceutical formulation of claim 6 wherein the compound is

9. The pharmaceutical formulation of claim 6 wherein the compound is

10. The pharmaceutical formulation of claim 6 wherein the pharmaceutical formulation is a dosage form for oral or parenteral administration.

11. A pharmaceutical formulation comprising one or more excipients and a group 6 compound selected from the group consisting of

wherein R 24 is —H, —CH 2 OH, —CH 2 OC(O)CH 3 , —OC(O)CH 3 or —CH 2 )C(O)OCH 3 .

12. The pharmaceutical formulation of claim 11 wherein the compound is

13. The pharmaceutical formulation of claim 11 wherein the compound is

14. The pharmaceutical formulation of claim 11 wherein the compound is

15. The pharmaceutical formulation of claim 11 wherein R 24 is —CH 2 OH.

16. The pharmaceutical formulation of claim 11 wherein the pharmaceutical formulation is a dosage form for oral or parenteral administration.

17. A compound wherein the compound is

(a) a group 2 compound selected from the group consisting of

(b) a group 3 compound selected from the group consisting of

(b) a group 6 compound selected from the group consisting of

wherein R 24 is —H, —CH 2 OH, —CH 2 OC(O)CH 3 , —OC(O)CH 3 or —CH 2 )C(O)OCH 3 .

18. The compound of claim 17 wherein the compound is in the form of a powder or granule.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057116/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057116/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057116/0451 →
CHANGE OF NAME Recorded Nov 2, 2012
From: HARBOR BIOSCIENCES, INC.
To: HARBOR DIVERSIFIED, INC.
Reel/Frame 029227/0929 →
CHANGE OF NAME Recorded Mar 3, 2010
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 024024/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2007
From: FRINCKE, JAMES M; LARDY, HENRY; MARWAH, PADMA
To: HOLLIS-EDEN PHARMACEUTICALS, INC.
Reel/Frame 019681/0090 →